During the last three months, 20 analysts shared their evaluations of Neurocrine Biosciences NBIX, revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 11 | 5 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 3 | 3 | 2 | 0 | 0 |
| 3M Ago | 1 | 6 | 2 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $166.7, along with a high estimate of $219.00 and a low estimate of $128.00. This upward trend is evident, with the current average reflecting a 2.93% increase from the previous average price target of $161.95.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Neurocrine Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $133.00 | $136.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $155.00 | $155.00 |
| Carter Gould | Barclays | Lowers | Overweight | $160.00 | $180.00 |
| Charles Duncan | Cantor Fitzgerald | Lowers | Overweight | $155.00 | $170.00 |
| Evan Seigerman | BMO Capital | Lowers | Market Perform | $128.00 | $142.00 |
| David Amsellem | Piper Sandler | Raises | Overweight | $159.00 | $131.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $136.00 | $143.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $190.00 | $190.00 |
| Akash Tewari | Jefferies | Raises | Buy | $189.00 | $177.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $181.00 | $173.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $190.00 | $160.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $143.00 | $136.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $180.00 | $170.00 |
| David Hoang | Citigroup | Raises | Neutral | $158.00 | $150.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $219.00 | $216.00 |
| Carter Gould | Barclays | Raises | Overweight | $180.00 | $169.00 |
| Brian Skorney | Baird | Raises | Outperform | $180.00 | $157.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $155.00 | $155.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Overweight | $170.00 | $160.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $173.00 | $169.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Neurocrine Biosciences. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This examination reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Neurocrine Biosciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
Discovering Neurocrine Biosciences: A Closer Look
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Neurocrine Biosciences's Financial Performance
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 30.37%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Neurocrine Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.92%, the company showcases efficient use of assets and strong financial health.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Understanding the Relevance of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
